0001193125-26-186943.txt : 20260428 0001193125-26-186943.hdr.sgml : 20260428 20260428160605 ACCESSION NUMBER: 0001193125-26-186943 CONFORMED SUBMISSION TYPE: 8-A12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20260428 DATE AS OF CHANGE: 20260428 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Seaport Therapeutics, Inc. CENTRAL INDEX KEY: 0002042347 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 992235719 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-A12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-43254 FILM NUMBER: 26907618 BUSINESS ADDRESS: STREET 1: 6 TIDE STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 617-807-4062 MAIL ADDRESS: STREET 1: 6 TIDE STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02110 8-A12B 1 d79444d8a12b.htm 8-A12B 8-A12B
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-A

 

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR (g) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

 

Seaport Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   99-2235719
(State of incorporation or organization)   (I.R.S. Employer Identification No.)

Seaport Therapeutics, Inc.

101 Seaport Blvd., Floor 12

Boston, Massachusetts

   02210
(Address of principal executive offices)   (Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class
to be so registered

  

Name of each exchange on which
each class is to be registered

Common Stock, par value $0.0001 per share   The Nasdaq Stock Market LLC

 

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

Securities Act registration statement file or Regulation A offering statement number to which this form relates (if applicable):

333-294976

Securities to be registered pursuant to Section 12(g) of the Act:

None

 

 
 

Item 1.

Description of Registrant’s Securities to be Registered.

For a description of Seaport Therapeutics, Inc.’s (the “Registrant”) common stock, par value $0.0001 per share (the “Common Stock”), to be registered hereunder, reference is made to the information set forth under the heading “Description of Capital Stock” in the Registrant’s prospectus that constitutes a part of the Registrant’s Registration Statement on Form S-1 (File No. 333-294976) initially filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), on April 10, 2026, including exhibits, and as amended from time to time (the “Registration Statement”), which information is hereby incorporated by reference. The description of the Common Stock included in any form of prospectus subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act that constitutes part of the Registration Statement shall be deemed to be incorporated by reference herein.

 

Item 2.

Exhibits.

In accordance with the “Instructions as to Exhibits” with respect to Form 8-A, no exhibits are required to be filed as part of this registration statement because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

   

SEAPORT THERAPEUTICS, INC.

Date: April 28, 2026

    

By:

  

/s/ Daphne Zohar

     

Daphne Zohar

     

Chief Executive Officer